medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2019, Number 2

<< Back Next >>

Residente 2019; 14 (2)

Syndrome of inappropriate antidiuretic hormone secretion and decreased bone mineral density

Jiménez-Bulnes J, De Anda-Maldonado H, Cruz-Sandoval G, Chavero-Flores CA, Guerrero-Reyna AG, Castro-Lizano N, Becerra-Alvarado IN, Alcaraz-López MF, Pérez-Guerrero EE, Saldaña-Cruz AM

Language: Spanish
References: 28
Page: 36-46
PDF size: 288.76 Kb.


ABSTRACT

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is defined by the constant release of anti-diuretic hormone (ADH). It is characterized by an hypotonic hyponatremia accompanied by an insufficient dilution of urine. Bone tissue is a great reservoir of sodium (Na) ions, which is why it can be considered as a possibility that the lack of Na could lead to a resorption of bone tissue and a consequential release of this ion, therefore leading to a diminished bone mineral density and an increased risk of fracture.


REFERENCES

  1. Ybarra MJ, De Leiva HA. Enfermedades de la neurohipófisis y la epífisis. En: Rodés TJ, Guardia MJ, editores. Medicina interna. 2ª ed. Barcelona: Ed. Masson; 2004. pp. 2447-2448.

  2. Velasco CM, Runkle VL. Current considerations in syndrome of inappropriate secretion of antidiuretic hormone/syndrome of inappropriate antidiuresis. Endocrinol Nutr. 2010; 57 (S2).

  3. Franco HS, Prieto PJ, Nalotto L. Síndrome de secreción inadecuada de hormona antidiurética. SEMERGEN. 2011; 37 (3): 497-498

  4. Sejling AS, Pedersen-Bjergaard U, Eiken P. Syndrome of inappropriate ADH secretion and severe osteoporosis. J Clin Endocrinol Metab. 2012; 97 (12): 4306-4310.

  5. Puras RP, Gómez RE. Hiponatremia recurrente secundaria a ISRS. Rev Asoc Esp Neuropsiq. 2014; 3011; 31 (112).

  6. Branten AJ, Wetzel M. Hyponatremia due to. Ann Neurol. 1998; 43 (2).

  7. Bouman WP Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998; 13 (1).

  8. Martínez-Cortés M, Ogando-Portilla N, Pecino-Esquerdo. Hiponatremia recurrente inducida por antidepresivos: a propósito de un caso. Actas Esp Psiquiatr. 2013; 41(6).

  9. Arinzon ZH, Lehman YA, Fidelman ZG, Krasnyansky I. Delayed recurrent SIADH associated with SSRIs. Ann Pharmacotherapy. 2002; 36 (7-8).

  10. Cuzzo B, Lappin SL. Vasopressin (antidiuretic hormone, ADH). StatPearls. 2018;

  11. Carrillo ER, Carvajar RR, Hernandez AC. Vasopresina: una nueva alternativa terapéutica en el. Rev Asoc Mex Med Crit y Ter Int. 2003; 17 (5).

  12. Perucca J, Bichet DG, Bardoux P et al. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008; 19: 1721-1731.

  13. Gutierrez VI. Síndrome de secreción inapropiada de hormona antidiuretica. In: Isauro G. La fisiopatología como base fundamental del diagnóstico clínico. México: Panamericana; 2011. pp. 580-582.

  14. Loffing J, Korbmacher C. Regulated sodium transport in the renal. Pflugers Arch. 2009; 458 (111-135).

  15. Burton R, Theodor P. Clinical Physiology of Acid-Base and Electrolyte Disorders. 2001: McGraw-Hill Education. 992.

  16. Murase T Ecelbarger CA, Becker EA et al. Kidney aquaporin-2 expression uring escape from antidiuresis is not related to plasma or tissue osmolality. J Am Soc Nephrol. 1999; 10: 2067-2075.

  17. Leaf A, Bartter FC, Santos RF et al. Syndrome in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest. 1953; 32: 868-878.

  18. Wheater PR, Burkitt HG, Daniels VG. Functional histology. New York: Churchill Livingstone ed.; 1987. pp. 142-60.

  19. Man Z, Larroudé MS. Osteoporosis. In: Molina J, Alarcón-Segovia D, Molina JF, Anaya JM, Cardiel MH. Texto de reumatología. Fundamentos de Medicina (CIB). 6 ed, 2005. pp. 456-481.

  20. Becker C. Pathophysiology and clinical manifestations of osteoporosis. Clin Cornerstone. 2006; 8: 19-27.

  21. Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354: 2250-2261.

  22. Aurbach GD, Marx SJ, Spiegel AM. Parathyroid hormone, calcitonin and the calciferols in Wilson y Foster, Williams Textbook of Endocrinology, 7th edition, WB Saunders 1985, p. 1136.

  23. Mineral metabolism and metabolic bone disease. In: Greenspan FS, Strewler GJ, eds. Basic and clinical endocrinology. 5a ed. New Jersey: Appleton & Lange, 1997. pp. 263-274.

  24. Pietschmann P, Rauner M, Sipos W, KerschanSchindl K. Osteoporosis: an age-related and gender-specific disease--a mini-review. Gerontology. 2009; 55: 3-12. 2.

  25. Bussmann C, Bast T. Hyponatraemia in children with acute CNS disease: SIADH or cerebral salt wasting? Child’s Nervous System. 2001; 17 (1-2): 58-62.

  26. Laville M, Burst V, Peri A, Verbalis JG. Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): therapeutic decision-making in real-life cases. Clinical Kidney Journal. 2013; 6 (Suppl 1): i1-i20. doi:10.1093/ckj/sft113.

  27. Alcázar R, Albalete P. Aspectos actuales en el tratamiento del síndrome de secreción inadecuada de hormona antidiurética. Los antagonistas de los receptores de la vasopresina en el tratamiento de los trastornos del agua. Madrid Nefrologia Sup Ext. 2011; 2 (6): 75-83.

  28. Albalate M, Alcázar R, De Sequera P. Alteraciones del sodio y del agua. In: Lorenzo V, López-Gómez JM, Martín de Francisco AL, Hernández D, eds. Nefrología al Día (1st ed.). Barcelona: Grupo Editorial Nefrología; 2010. pp. 163-80.




2020     |     www.medigraphic.com